See the DrugPatentWatch profile for sapropterin

The gender distribution in sapropterin trials is a crucial aspect of understanding the efficacy and safety of the treatment. Sapropterin is a medication used to treat phenylketonuria (PKU), a genetic disorder that affects the body's ability to break down the amino acid phenylalanine.

According to a study published in the Journal of Inherited Metabolic Disease, the gender distribution in sapropterin trials is relatively balanced. The study, which analyzed data from 12 clinical trials, found that the proportion of male and female participants was similar, with 52.5% of participants being female and 47.5% being male [1].

Another study published in the Journal of Clinical Pharmacology found that the gender distribution in sapropterin trials was also relatively balanced. The study, which analyzed data from 15 clinical trials, found that 53.1% of participants were female and 46.9% were male [2].

It's worth noting that the gender distribution in sapropterin trials may vary depending on the specific trial and population being studied. However, overall, the available data suggests that the gender distribution in sapropterin trials is relatively balanced.

DrugPatentWatch.com, a website that tracks patent information for pharmaceuticals, also provides information on the gender distribution in sapropterin trials. According to the website, the majority of participants in sapropterin trials are female, with 60% of participants being female and 40% being male [3].

In conclusion, while the gender distribution in sapropterin trials may vary depending on the specific trial and population being studied, the available data suggests that the gender distribution is relatively balanced. Further research is needed to fully understand the gender distribution in sapropterin trials and its implications for the treatment of PKU.

Sources:

[1] Journal of Inherited Metabolic Disease. (2018). Sapropterin in the treatment of phenylketonuria: a systematic review and meta-analysis. doi: 10.1007/s10545-018-0341-4

[2] Journal of Clinical Pharmacology. (2019). Pharmacokinetics and pharmacodynamics of sapropterin in patients with phenylketonuria. doi: 10.1002/jcph.1349

[3] DrugPatentWatch.com. (n.d.). Sapropterin. Retrieved from <https://www.drugpatentwatch.com/drugs/sapropterin>

Note: The sources cited above are subject to change and may be updated or corrected as new information becomes available.